国产房水引流置入物治疗顽固性 青光眼近期疗效观察

目的观察国产房水引流置入物治疗顽固性青光眼的近期疗效。方法采用自行设计、北京市橡胶制品设计研究院生产的房水引流置入物，共治疗４０例（４１只眼）顽固性青光眼，其中新生血管性青光眼１６只眼，其它青光眼２５只眼。结果术后随访３～２７个月，平均９．２个月，新生血管性青光眼的眼压，由术前７．２０±１．５１ｋＰａ（１ｋＰａ＝７．５ｍｍＨｇ）降至术后２．４０±１．３３ｋＰａ，其它青光眼的眼压，由术前６．２７±１．０７ｋＰａ降至术后２．００±２．９３ｋＰａ；成功率分别为８１％和８４％。术后常见并发症有浅前房、前房积血、脉络膜脱离等。结论国产房水引流置入物经济、简便，是治疗顽固性青光眼的有效方法之一。

A short term clinical study on a new aqueous humor drainage implant for refractory glaucoma

OBJECTIVE: To investigate the therapeutic effect of a new aqueous humor drainage implant made in China for treatment of refractory glaucoma. METHODS: The implant was designed by ourselves and manufactured by Beijing Rubber Products Design & Research Institute. From July 1993 to September 1995, we observed 40 cases (41 eyes) with refractory glaucoma treated with the implantation surgery, including neovascular glaucoma (NVG) 16 eyes, non-neovascular glaucoma (NNVG) 25 eyes. RESULTS: The mean period of postoperative follow-up was 9.2 (range 3-27 months) months, the IOP was lowered from preoperative 7.20 +/- 1.51 kPa to postoperative 2.40 +/- 1.33 kPa in NVG group and from preoperative 6.27 +/- 1.07 kPa to postoperative 2.00 +/- 2.93 kPa in NNVG group. The success rate was 81% in NVG group and 84% in NNVG group. The common postoperative complications were flat anterior chamber, hyphema, choroidal detachment and so on. CONCLUSIONS: Our newly designed aqueous humordrainage implant provides an economic implant in China. The method of implantation is simple, is one of the effective methods for treatment of refractory glaucoma and can be widely used in clinics.